CAMBRIDGE, 10th July 2019 -
Cambridge Cancer Genomics (CCG.ai) welcomes Dr. Philip Beer onto the team as Head of Translational Medicine. Philip is a physician scientist and precision oncology specialist; he brings years of expertise in clinical cancer genomics, both in the NHS and commercially.
Philip has extensive experience working on bringing cancer genomics into clinical practice through diverse roles in academia, clinical research, genomic strategy, and in medical advisory roles. He is the perfect person to help shape CCG.ai’s clinical strategy and clinical prediction tools.
Dr. John Cassidy, CEO at Cambridge Cancer Genomics said “We are thrilled to welcome Dr Beer onto the team at CCG.ai. Philip brings a wealth of experience in the clinical translation of genomics technologies both within the NHS and in the wider health ecosystem. His experience and guidance will add to the already considerable computational talent added to the CCG.ai team over the last year.”
“Modern computational techniques have the potential to unlock the full clinical power of cancer genomics. CCG.ai have built a stellar team which I am very excited to be joining.” commented Dr. Philip Beer.
About Cambridge Cancer Genomics
Cambridge Cancer Genomics (CCG.ai) is a Y Combinator backed startup building the underlying tools to empower oncologists to make the best therapeutic decisions for their patients. Their precision AI platform, OncOS, is fast becoming the global open standard for next generation sequencing analysis and clinical decision support in cancer medicine. By focussing on machine learning based analytics of serial liquid biopsy samples, CCG.ai is building predictive models to understand how tumors evolve and how this can impact on response to therapy. As this knowledge base of tumor genomic evolution increases, OncOS will become the operating system for personalised cancer medicine. At CCG.ai, our mission is to ensure every patient gets the right drug, at the right time, to beat their cancer.
For more details, or to request an interview, please contact: Press@CCG.ai